Return to homepagePandemic Pact

Identification and validation of immunometabolic markers that increase the susceptibility to develop severe forms of SARS-COV-2 infection.

  • Funded by Consejo Nacional de Ciencia y Tecnología (CONACYT)
  • Total publications:5 publications

Grant number: 311880

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Known Financial Commitments (USD)

    $0

  • Funder

    Consejo Nacional de Ciencia y Tecnología (CONACYT)

  • Research Location

    Mexico

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Prognostic factors for disease severity

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Development And Validation Of Diagnostic Or Prognostic Tools, Sensitive And Specific

5 Publications linked via Europe PMC

Last Updated:4 days ago

View all publications at Europe PMC

The plasma metabolome of long COVID patients two years after infection.

miR-146a, miR-221, and miR-155 are Involved in Inflammatory Immune Response in Severe COVID-19 Patients.

Immunometabolic signatures predict risk of progression to sepsis in COVID-19.

Targeted metabolomics identifies high performing diagnostic and prognostic biomarkers for COVID-19.

Clinical Factors Associated with COVID-19 Severity in Mexican Patients: Cross-Sectional Analysis from a Multicentric Hospital Study.